International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 38
  • Journal CiteScore: 46.78
  • Journal Impact Factor: 1.95
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Ozonides as promising anticancer agents

17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems
October 04-06, 2018 Moscow, Russia

Ivan A Yaremenko, Anatoliy E Vilikotskiy, Yulia Yu Belyakova, Peter S Radulov, Alexander O Terentev and Fabrice Fleury

N D Zelinsky Institute of Organic Chemistry-RAS, Russia University of Nantes, France

Posters & Accepted Abstracts: Int J Drug Dev & Res


Organic peroxides have significant potential for creating on their basis new medicinal agents. In recent decades, the chemistry of organic peroxides has been intensively developing due to the detection of antimalarial, anthelmintic, antitumor, growth regulation, and antitubercular activity. The greatest progress in the development of medicinal agents on the base of synthetic peroxides is associated with compounds that contain an ozonide (1, 2, 4-trioxolane) moiety. In our studies, a general approach to the preparation of bicyclic ozonides is developed via reaction of 1,5-diketones with H2O2, promoted by such acids as BF3 Et2O, H2SO4, p-TsOH and HBF4. This process leads to the stereoisomeric bridged ozonides and provides a rare example of selective synthesis of ozonides without the use of ozone. Synthesized ozonides from 1,5-diketones and H2O2 have high cytotoxicity in vitro and selectivity against HepG2, A549, PC3, and DU145 cancer cell lines, which in some cases is higher than that of paclitaxel, doxorubicin, cisplatin, artemisinin, artesunic acid. This work was supported by RFBR according to the research project ΓΆΒ?Β? 18-53-15010 and Projets de Recherche Conjoints (PRC) – CNRS, PRC Russie 2017 CNRS

Biography :

Dr Ivan A Yaremenko has completed his PhD in Organic Chemistry by N D Zelinsky Institute of Organic Chemistry RAS in 2013. At present he is researcher N D Zelinsky Institute of Organic Chemistry RAS. He published 21 research papers, and 11 patents

E-mail:  [email protected]